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Background: Dysregulation of autophagy is important in the pathogenesis of many diseases, including cancer.
Several aspects of the biological role of autophagy are however still unclear and the relationship between
apoptosis and autophagy, particularly in the liver has yet to be thoroughly explored. In this study we evaluated the
expression of Beclin 1 (one of the main autophagocytic agents, which bridges autophagy, apoptosis and both
differentiation), and both pro- (Bad, Bax) and anti-apoptotic (Bcl-2, Bcl-xL) factors in liver samples from patients with
different stages of liver disease.
Methods: The study concerned 93 patients from 49 cases of chronic hepatitis (CH) (30 HCV and 19 HBV-related), 13
of cirrhosis (CIRR) (10 HCV and 3 HBV-related), 21 of hepatocellular carcinoma (both HCC and peritumoral tissues
[PHCC]), and 10 controls (CONTR). Real-time PCR and Western blotting were used to measure mRNA and protein
expression levels.
Results: Beclin 1 mRNA levels were lower in HCC than in CH (P = 0.010) or CIRR (P = 0.011), and so were the Bcl-xL
transcripts (P < 0.0001). Bad mRNA levels were higher in CH and CIRR than in CONTR, while Bax transcripts were
increased in all tissues (P = 0.036). PHCC expressed the highest Bcl-2 mRNA levels. HBV-related CH tissues showed
significantly higher Bcl-xL and Bad mRNA levels than HCV-related CH (P = 0.003 and P = 0.016, respectively).
Conclusions: High Beclin 1, Bcl-xL and Bad levels in CH and CIRR tissues suggest an interaction between
autophagy and apoptosis in the early and intermediate stages of viral hepatitis. In HCC these processes seem to be
downregulated, probably enabling the survival and growth of neoplastic hepatocytes.
Keywords: Autophagy, B and C virus infection, Beclin 1, Hepatocellular carcinoma, Pro- and anti-apoptotic factors.Background
Autophagy (“self-digestion”) is a highly-regulated process,
important in cellular homeostasis and involved in the turn-
over of long-lived proteins and damaged cellular orga-
nelles. Autophagy is like a two faces coin since in some
cellular settings it becomes a cell survival pathway, with
suppression of apoptosis, while in others, it leads to cell
death, either in association with apoptosis or when apop-
tosis is defective [1].
Although autophagy is thought to be predominantly a cell
survival mechanism, linked to a variety of physiological con-
ditions such as aging, degenerative processes and nutrient* Correspondence: marina.bortolami@unipd.it
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reproduction in any medium, provided the orstarvation, plenty of evidence points to it having an essential
role also in the pathogenesis of several human diseases. The
importance of autophagy as a homeostatic and survival-
promoting mechanism is indeed underscored by the demon-
stration of a defective autophagy in the etiology of many
pathologies, such as Crohn’s disease, stroke, neurodegenera-
tive disorders and pancreatic damage [2].
Autophagy is also involved in the carcinogenic process [3].
One of the main factors regulating autophagy is the human
beclin-1 gene, located on chromosome 17q21, monoalleli-
cally deleted in 40-75% of sporadic breast, prostate, and ovar-
ian tumors [4]. Mice mutant for the gene coding for Beclin 1
have a relatively high incidence of spontaneous tumors, thus
suggesting that a downregulated autophagy may increase the
cells’ susceptibility to transformation [5]. A reduced Beclin 1Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cancers, including glioblastomas [6], ovarian [7], lung [8],
and esophageal cancers [9]. On the other hand, Beclin 1 ex-
pression is reportedly increased in colorectal and gastric can-
cer cells [10,11] and these discrepant results indicate that
Beclin 1 probably has different functions in different tissues.
Although the relationship between apoptosis and autop-
hagy is still a debated topic, there are crucial proteins
involved in the crosstalk involved in both processes. Many
apoptotic and anti-apoptotic signals depend on interactions
between Bcl-2 and other members of the Bcl-2 family. Bcl-
2 is an anti-apoptotic factor that may also suppress autop-
hagy by physically interacting with Beclin 1 [12,13], which
has a so-called BH3 domain [14] that mediates the interac-
tions with Bcl-2 and other homologs, such as Bcl-xL [15].
Beclin 1 indeed binds to Bcl-2 and Bcl-xL, through a BH3-
BH3 receptor interaction and BH3-only proteins (i.e. proteins
that share also with the wider Bcl-2 family the BH3 domain,
that is critical for their killing capacity) stimulate autophagy
by competitively disrupting this interaction and consequently
leading to the release of Beclin 1 from its inhibitors.
The role of autophagy in chronic liver diseases is not well
understood. To our knowledge, there are no data available
on the behavior of Beclin 1 in chronic hepatitis (CH) and
cirrhosis (CIRR), and very few as regards hepatocellular car-
cinoma (HCC), which is one of the most common and le-
thal tumors worldwide, and a late complication of chronic
viral hepatitis and cirrhosis in more than 80% of cases [16].
The biological significance of the interaction between
Beclin 1 and Bcl-2 in the liver has yet to be thoroughly
explored. In this study, we evaluated Beclin 1 expression in
liver tissues from patients with chronic liver diseases and
HCC, looking for correlations, if any, with apoptotic and
anti-apoptotic members of the Bcl-2 family.Methods
Patients
This study involved 93 patients
A first group included 49 patients with chronic hepatitis
(CH): 30 HCV-related 9 females, 21 males; mean age
42.6±12.9 years; range 20–67; HCV-genotypes: 14 HCV-1, 8
HCV-2, 5 HCV-3, 3 HCV-4), and 19 HBV-related (3 females,
16 males; mean age 44±11.1 years; range 32–63).
The second group included 13 cirrhotic patients (CIRR): 3
HBV-related (1 female, 2 males; mean age 52.7 ± 4.1 years;
range 48–56) and 10 HCV-related (2 females, 8 males;
mean age 53.1± 13.1 years; range 33–69).
The third group consisted of 21 patients with HCC in cir-
rhosis: 9 HCV-related (4 females, 5 males; mean age
61.2 ±15.5 years; range 23–75) and 3 HBV-related (1 female,
2 males; mean age 65.7 ±9.9 years; range 55–78); and 9
patients with HCC in non-virus-related cirrhosis (2 females,
7 males; mean age 58.8 ± 8.1 years; range 46–72).As “control” specimens (Control), liver biopsy samples from
3 patients who had undergone cholecystectomy (2 females, 1
male; mean age 44.6±18.6 years; range 25–62) and 7 patients
operated for liver metastases (4 females, 3 males; mean age
57.6±15 years; range 29–73) were considered.
The diagnosis of chronic HCV-related hepatitis was
obtained on the basis of HCV-RNA positivity by polymer-
ase chain reaction (PCR), persistently abnormal transami-
nases for at least 12 months, and a compatible histology.
Histological diagnoses were made by a single pathologist
and scored, according to Ishak’s classification [17], in all bi-
opsy samples. Before biopsy, each patient was tested to
measure HCV antibodies.
All the following studies were performed prior to any
treatment.
All the patients, enrolled in this study, were recruited
from the Department of Surgery, Oncology and Gastro-
enterology, DiSCOG, University of Padova, School of Medi-
cine, Italy. Informed consent was obtained from each
patient included in the study and the study protocol con-
formed to the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by the Ethical
Committee of Padova University and of the Padova Univer-
sity Hospital Ethic Committee.
Liver samples
During a US-guided procedure (with a 16–18 gauge modified
Menghini needle), liver biopsies were obtained from patients
with chronic hepatitis or liver cirrhosis according to a standard
protocol. One part of the liver specimen, at least 2 cm long,
was used for diagnostic purposes while the remainder was im-
mediately frozen in liquid nitrogen and stored at −80°C.
Tissue samples were obtained from HCC at the time of
surgical resection. Tumor tissues used for mRNA extraction
were macroscopically selected in the middle of the nodule.
The corresponding non-cancerous tissues (PHCC) were
taken at least 1 cm (more where possible) from the edge of
the tumor in the resected specimen. To check for any pres-
ence of infiltrating tumor cells, a slice of the sample was
fixed in buffered formaldehyde, stained with haematoxylin
and eosin and examined by the pathologist. In all cases, care
was taken during the surgical procedure to avoid contamin-
ation between cancerous and non-cancerous samples.
All surgical liver specimens were cut into small pieces, im-
mediately snap frozen in liquid nitrogen, then stored at −80°C.
The routine histological analysis was done in blind fash-
ion by the pathologist. HCC lesions were classified as well-,
moderately- or poorly-differentiated according to the
Edmonson & Steiner criteria [18], grading the specimens
on the basis of the predominant findings.
Virological and biochemical assessments
In all HCV-infected patients, HCV-specific serum anti-
bodies were detected by enzyme immunoassay (EIA-II;
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immunoblot assay (RIBA-II; Ortho Diagnostic System)
according to the manufacturer’s instructions. HCV RNA was
detected with a standardized polymerase chain reaction
(PCR) (Amplicor, Roche Diagnostic Systems, Neuilly, France)
in the total RNA extracted from biopsies.
HCV genotype was determined by the Inno-Lipa II HCV
method (Innogenetics S.A., Gent Belgium). HCV genotypes
were classified as genotype 1, subtypes 1a and 1b, and the
remaining subtypes of types 2, 3, and 4 were pooled under
each corresponding genotype.
HBV serum markers were tested by radio-immune assay
(RIA) (Abbott, Chicago-Illinois, USA), while HBV-DNA was
tested with a commercially-available fluid phase hybridization
assay (Abbott, Chicago-Illinois, USA).
Data regarding transaminases were obtained.
RNA isolation
Total RNA was extracted from frozen hepatic tissue with
acid guanidium thiocyanate-phenol-chloroform according
to the Chomczynski and Sacchi method [19]. RNA concen-
trations were quantified spectrophotometrically. Integrity of
the RNA sample was assessed by electrophoresis on a 2%
agarose gel (FMC Bio Product, Rockland, ME, USA) con-
taining ethidium bromide. The quality of the RNA isolated
was also assessed using the RNA 6000 Nano Assay and the
Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto,
CA, USA).
Reverse transcription
For the synthesis of complementary DNA (cDNA), 2 μg of
RNA were reverse transcribed in a final volume of 40 μl in
the presence of 1X PCR buffer, 1 mM each of dNTPs
(dATP, dTTP, dCTP, dGTP), 1U μl −1 RNase inhibitor, 2.5
μM random hexamers, and 2.5 U μl −1 of murine leukemia
virus (Perkin Elmer, Foster City, CA, USA).
The reverse transcription reaction was completed at 25°C
for 10 min, 42°C for 15 min and 99°C for 5 min, in a Perkin
Elmer GeneAmp PCR System 2400.
The cDNA was stored at −20°C.
Primers
Oligonucleotide primers were designed with the Primer
Express software rel. 1.0 (ABI/PE Applied Biosystems, Foster
City, CA, USA) and synthesized by Primm srl (San Raffaele
Biomedical Science Park, Milano, Italy). Nucleotide
sequences for the sense and antisense primers used for real-
time PCR were: 5’-GAGGGATGGAAGGGTCTAAG-3’, 5’-
GCCTGGGCTGTGGTAAGT-3’ for Beclin-1 [ENST000003
61523], and the length of this amplicon was 159 bp; 5’-
GGATCCAGGATAACGGAGGC-3’, 5’-CCAGATAGGCAC
CCAGGGT-3’ for Bcl-2 [ENST00000306316], and the length
of this amplicon was 147 bp; 5’-GGCAGGCGACGAGT
TTGA-3’, 5’-CCCATCCCGGAAGAGTTCAT-3’ for Bcl-xL[ENST00000376062], and the length of this amplicon was
127 bp 5’-CCTGGCACCCAGCACAA-3’, 5’-GCCGATC
CACACGGAGTACT for β-actin [ENST 00000158302],
and the length of this amplicon was 70 bp.
5’-GGAGGATGAGTGACGAGTTTGTG-3’, 5’-GGGT
GGAGTTTCGGGATGT-3’ for Bad [ENST00000265480],
and the length of this amplicon was 193 bp; 5'-CT
TTTGCTTCAGGGTTTCATCC-3', 5'-TTGAGACACTC
GCTCAGCTTCT-3' for Bax [ENST00000356483], and the
length of this amplicon was 119 bp.
PCR product analysis
PCR products underwent vertical electrophoresis on a
0.75 mm thick, non-denaturing 6% acrylamide/bis-acryl-
amide gel with 5% glycerol. The silver-nitrate-stained
bands were scanned on a densitometer and image
analyzer system (Quantity-one- BIO-RAD Hercules, CA,
USA).
DNA purification
Purified DNAs were obtained using the MinElute PCR
Purification Kit according to the manufacturer’s protocol.
The concentration of the purified amplicons was quanti-
fied spectrophotometrically with the Biophotometer 6131
(Eppendorf, Hamburg, Germany) and the PicoGreen ds-
DNA quantitation reagent and kits.
Fluorescence was measured with the LS-5 Luminescence
Spectrometer (Perkin Elmer, Foster City, CA) using 480 nm
excitation and 520 nm emission.
Quantitative absolute real-time PCR
Real-time PCR was conducted in an ABI 7900 Sequence De-
tection System (Applied Biosystems, Foster City, CA, USA)
using SYBR Green I [20]. The reaction was obtained on 96-
well plates, in a 25μL final volume containing 1X TaqMan
buffer, 5.5 mmol of MgCl2, 200 μmol of nucleotides, 0.01U
mL-1 of AmpErase UNG, 0.25U of AmpliTaq Gold Polymer-
ase (SYBR Green Master Mix), 300nM of each primer and
5μL of cDNA template. After one 2-min step at 50°C and a
second step at 95°C for 10 min, samples underwent 45 cycles
of 45 s at 94°C and then: 45 s at 60°C for Beclin-1, Bcl-XL,
Bax and β-actin; 45 s at 62°C for Bcl-2 and 45 s at 65°C for
Bad. A final extension step was performed at 60°C for
10 min. All tests were performed in triplicate. Samples in
which the cDNA was omitted were used as negative
controls.
Gene expression quantification
The amounts of mRNA in the unknown samples were
determined from the standard curves of the gene of
interest [21]. Standards curves were generated using ser-
ial diluition (1:10) from 108 to 102 copies/μl of a refer-
ence sample.
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amounts of the gene of interest to the β-actin transcript
used as housekeeping gene.
Western blot analysis
Total protein extracts were obtained by homogenizing liver
tissues with RIPA lysis buffer (20 mM TrisHCl pH 7.4,
150 mM NaCl, 5 mM ethylene diamine tetra-acetic acid
[EDTA], 1.5% Niaproof, 1 mM sodium orthovanadate
Na3VO4 0.1% sodium dodecyl sulfate [SDS]). Protein con-
centration was determined using the RC DC Protein Assay
(Bio-Rad, Hercules, CA, USA). 40 μg of boiled proteins were
loaded onto the gel. Proteins were separated by SDS-PAGE,
transferred onto nitrocellulose membrane (Hybond ECL, GE
Healthcare Buckinghamshire, UK) and blocked with fat-free
milk [5% in Tween-phosphate-buffered saline (PBS)] for 1 h.
Membranes were probed with the primary mouse monoclo-
nal antibody against human Beclin-1 (1:200), Bcl-2 (1:1000),
Bcl-XL (1:200), Bad (1:500), Bax (1:500), and the primary
mouse monoclonal antibody against β-actin (1:1000) (Santa
Cruz Biotechnologies, California, USA). After incubation
with the secondary antibody (goat anti-mouse IgG, at a di-
lution of 1:10000), immunoreactive proteins were visua-
lized by chemiluminescence using SuperSignal WestPico
Chemiluminescent Substrate (Pierce) and captured on X-
ray film (Hyperfilm TM ECL, GE Healthcare, Buckingham-
shire, UK). Molecular sizing was carried out using the Full-
Range Rainbow Molecular weight Marker (GE Healthcare,
Buckinghamshire, UK). Exposed films were digitized and
the bands were semi-quantitatively evaluated by densito-
metric analysis. The Beclin-1, Bcl-2, Bcl-XL, Bad and Bax
protein expression levels were thus normalized to those of
the housekeeping gene, β-actin.
Statistical analysis
All results are given as mean values ± SD (standard devi-
ation). Statistical analyses were performed using the StatSoft
software, rel. 5.0 (Tulsa, OK, USA). Differences between
groups were analyzed with the Kruskal-Wallis test or Mann–
Whitney U test, as appropriate. Two-tailed P value<0.05
were deemed to be significant. The relationship between two
variables was determined using Spearman’s rank correlation
analysis.
Results
The Beclin 1, Bcl-2, Bcl-xL, Bad and Bax mRNA levels
expressed in the liver tissues are shown in Figure 1 and
Figure 2.
Beclin 1 mRNA expression
Beclin 1 mRNA levels were significantly lower in HCC
tissues than in CH or CIRR (30.84 ± 17.1 vs 42.65 ± 20.6;
P = 0.023 and 45.80 ± 18.4; P = 0.028, respectively), while
there was no difference with PHCC tissues (Figure 1A).There were no significant differences either in Beclin 1
mRNA levels between HCV-related versus HBV-related
CH (39.67 ± 19.57 vs 47.36 ± 21.8).
Bcl-2 mRNA expression
The Kruskal Wallis test revealed a statistically significant
difference (P=0.0003) in the Bcl-2 transcript levels among
the various groups, with PHCC tissues expressing the high-
est Bcl-2 levels (7.28±3.4) when compared with Contr
(4.16±1.6; P=0.009), CH (3.83±1.4; P <0.0001) and CIRR
(4.60±1.3; P=0.023) (Figure 1B).
There were no differences in Bcl-2 mRNA expression in
the CH tissues in relation to the type of viral infection
involved (HBV-HCV), but statistically significant differ-
ences were found between PHCC HCV (7.65±3.8) and
both CH HCV-infected tissues (3.79±1.1; P=0.012) and
Contr (4.163.79±1.1; P=0.04).
Bcl-xL mRNA expression
The Kruskal Wallis test showed a statistically significant dif-
ference (P< 0.0001) among the various groups. The mean
Bcl-xL transcript levels were significantly lower in HCC
(59.04±22.9) than in PHCC (93.14±37.1, P=0.001), CIRR
(112.01±53.4, P=0.001), CH (117.54±56.3, P <0.0001) or
Contr (97.25±34.4; P=0.004) (Figure 1C).
A statistically significant difference was also found in the CH
tissues according to the disease’s etiology, with HCV-related
CH showing lower Bcl-xL expression than HBV-related CH
(96.53±34.2 versus 150.73±68.3, P=0.003) (Figure 2A).
These differences were confirmed also considering only
HCV-infected tissues: Bcl-xL mRNA expression in HCC
(64.92±29.9) was significantly lower than in CIRR
(107.50±47.6, P=0.05) or CH (96.53±34.2, P=0.023).
Moreover, when only cases of HCV-related hepatitis were
considered, patients with HCV genotype 1 infection had a
statistically lower Bcl-xL mRNA expression (75.38±19.0)
than cases with genotype 2 (114.57±34.3, P=0.010), or
genotype 3 (104.85±22.4, P=0.019).
Bad mRNA expression
A statistically significant difference (P<0.0001 Kruskal Wallis
test) emerged in this parameter among the five groups
considered.
Contr had the lowest Bad mRNA expression (1.59±0.6),
and the difference was statistically significant versus CH
(4.32±1.8; P<0.0001), CIRR (3.68±1.7; P=0.007) and PHCC
(2.71±1.51; P=0.017). A statistically significant reduction in
Bad mRNA levels was found going from CH to PHCC
(P=0.0001) and HCC (2.50±1.5; P=0.0009) (Figure 1D).
Bad mRNA levels in HBV-related CH tissues were sig-
nificantly higher (5.84±2.0) than in the HCV-related CH
tissues (3.93±1.6; P= 0.016) (Figure 2B) and patients with
genotype 1 HCV (3.93±1.2) expressed higher Bad mRNA























































































































Figure 1 mRNA analysis by quantitative absolute Real-Time PCR using SYBR Green I. Gene analysis of Beclin 1 (A), Bcl-2 (B), Bcl-xL (C), Bad
(D) and Bax (E). Control: control specimens; CH: chronic hepatitis; CIRR: cirrhosis; PHCC: cirrhotic tissues surrounding hepatocellular carcinoma;
HCC: hepatocellular carcinoma. Data are expressed as mean± SD of the ratio of the gene of interest to that of β-actin.
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The Kruskal Wallis test indicated a significant difference in
this parameter (P=0.026) among the various groups.
Again, Contr expressed the lowest Bax mRNA levels





















Figure 2 Bcl-xL and Bad mRNA transcripts in chronic hepatitis HBV- a
are expressed as mean± SD.CH (6.61± 2.6; P=0.003), CIRR (6.80±2.4; P =0.05),
PHCC (7.35± 3.4; P =0.007) or HCC (7.99± 3.8; P =0.004)
(Figure 1E).
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type 1 (7.62 ± 3.0) than in HCV genotype 3 (4.60 ±1.7;
P = 0.033).Western blot
Beclin 1, Bcl-2, Bcl-xL, Bad and Bax protein expressions
were assessed only in the surgical liver tissues from 13
HCC patients (both in the cancer and in the surrounding
cirrhotic tissue). Like the mRNA expression in these tissues,
the Beclin 1, Bcl-2, Bcl-xL Bad and Bax protein expression

















































































Figure 3 Protein expression in HCC and the corresponding tissues su
(C); Bad (D); Bax (E). P: cirrhotic liver tissues surrounding hepatocellular car
the optical density ratio of genes to β-actin. Values are reported as mean vin HCC compared to tissues surrounding tumors, however
without reaching the statistical significant difference as
found for Bcl-xL mRNA expression (Figure 3).Correlation analysis
A significant positive correlation emerged between Beclin 1
and Bcl-xL mRNA expression in CH (r= 0.69; P< 0.0001),
CIRR (r= 0.84; P=0.0008), and HCC (r= 0.67; P=0.002),
and when all tissues were considered together (r = 0.64;
P <0.0001) (Figure 4A). This correlation was also significant
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rrounding HCC. Western blot analysis of: Beclin 1 (A); Bcl-2 (B); Bcl-xL
cinoma; HCC: tumoral tissues of 8/13 patients. Data are expressed as
alues ± SD.
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Figure 4 Linear regression analysis. Results of the linear regression analysis of: Beclin 1/β-actin vs Bcl-xL/β-actin (A); Beclin 1/β-actin vs Bad/β-
actin (B) in all tissues considered.
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emerged for Beclin 1 and Bcl-xL mRNA expression in
HBV-related CH tissues (r = 0.88; P <0.0001).
An inverse correlation was found between Beclin 1 and
Bcl-2 in HCC tissues (r =−0.53; P = 0.03) while a positive
correlation in PHCC was identified (r = 0.54; P = 0.01).
Positive correlations were identified between Beclin 1 and
Bax in CH (r= 0.49; P = 0.003) and also in HCV-related
CH alone (r = 0.57; P = 0.002). Positive correlations were
also observed between Beclin-1 and Bad when all tissues
were considered (r= 0.23; P = 0.003) (Figure 4B) and in
particularly in PHCC (r= 0.63; P = 0.003). While an inverse
correlation was found between Bcl-2 and Bcl-xL in HCC
(r=−0.58; P = 0.01).
Discussion
In this study we evaluated the expression of Beclin 1 and
of some pro- and anti-apoptotic members of the Bcl-2
family in liver tissues obtained from chronic liver disease
patients in various stages in a cross-sectional study with a
view to shedding light on their role in the natural history
of chronic liver disease and its progression from chronic
hepatitis to cirrhosis and hepatocellular carcinoma.
Beclin 1 expression in chronic liver disease
Beclin 1 is one of the main autophagocytic agents, a regula-
tor gene that bridges autophagy, apoptosis and differenti-
ation. In our study, Beclin 1 mRNA expression was
constitutive of all the tissues examined (in contrast with
what previously described by Shi Yh et al. [22]) and the
highest Beclin 1 mRNA levels were found in cirrhotic liver
tissues in the absence of HCC. The significantly lower
Beclin 1 mRNA expression seen in HCC by comparison
with non-cancerous CH and CIRR tissues probably reflects
previous observations in other types of human tumor, e.g.
in ovarian, breast, prostate and lung cancer [8]. On the
other hand, previous data obtained in liver studies using
cDNA microarray analysis actually demonstrated an upre-
gulated Beclin 1 mRNA expression in HCC [23]. Danielet al. [24] compared Beclin 1 mRNA expression in HCC
with adjacent non-tumor tissues and found similar mean
transcript levels, although the ratio of the Beclin 1 mRNA
expression in the tumor/non-tumor tissue varied consider-
ably between different patients. Shi Yh et al. [22] found that
only 31.7% of HCC had Beclin 1 expression and that HCC
patients with positive Beclin 1 expression had a significantly
better prognosis both in terms of disease-free and of overall
survival. Using a quantitative absolute real-time PCR and
Western blot analysis, respectively, we found no significant
differences in Beclin 1 transcript or protein expression be-
tween HCC and surrounding tissues, while no data are
available at the moment with respect to patient survival in
our series. In any case, our aim was not to correlate Beclin
1 or other parameters to HCC patients survival but to de-
scribe the interactions between autophagy and apoptosis in
the natural history of chronic liver disease.
The low Beclin 1 mRNA levels detected in our HCC tis-
sues (compared with CH and CIRR without tumor) support
the hypothesis that a downregulated autophagy can con-
tribute to tumor progression. Malignant cells frequently
display low levels of autophagocytic activity [25], and this
may coincide with a greater chromosome instability, conse-
quently favoring tumorigenesis [3]. On the other hand, a
defective autophagy in tumor cells may result in their
impaired survival in the hostile microenvironment, thus
leading to tumor cell death that triggers chronic inflamma-
tion and an increased release of cytokines, which again may
enhance tumor growth [25].
Beclin 1 and HBV and HCV infection
Autophagy also has an important role in response to viral in-
fection. HCV replication is a process occurring in association
with intracellular structures, i.e. lipid droplets that interact
with other organelles such as the endoplasmic reticulum
(ER) [26], where HCV proteins-assembly takes place. In fact,
the HCV replication is compartmentalized by lipid bilayer
membranes and in infected hepatocytes, HCV replication
may induce the accumulation of autophagosomes, which
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somal fusion, inducing ER stress [27]. In our HCV-
infected tissues, we found no statistically significant differ-
ences in Beclin 1 transcript levels with the progression of
liver damage or the HCV genotype (as previously reported
also by Ait-Goughoulte M et al. [28]), a fact that suggests
that HCV viral proteins are not directly involved in modu-
lating Beclin 1 expression. The absence of any statistically
significant difference in Beclin 1 expression in tissues from
patients with HCV- versus HBV-related CH suggest that
the higher Beclin 1 expression levels seen in hepatitis are
an epiphenomenon of inflammation, prone to a burn-out
process in the more advanced phases, and that this process
takes place irrespective of the type of virus involved.
Apoptotic mediators in chronic liver diseases
To investigate the crosstalk between autophagy and apop-
tosis in human chronic liver disease, we analyzed pro- (Bax
and Bad) and anti-apoptotic (Bcl-2, Bcl-xL) members of the
Bcl-2 family.
As concerns the pro-apoptotic members, we found a
downregulation of Bad levels in PHCC and HCC. BH3-
only proteins, such as Bad [29], are cell death initiators The
overexpression of BH3-only molecules leads to apoptosis
and loss of genetic function. Bad selectively heterodimerizes
with Bcl-xL and Bcl-2, but not with other family members,
and when Bad binds to Bcl-xL and Bcl-2, it neutralizes their
anti-apoptotic activity. Also Bax has been shown to homo-
dimerize as well as heterodimerize with Bcl-2. Typically, a
translocation of about 20% of cellular Bax from the cyto-
plasm to the mitochondrial outer membrane is sufficient to
induce apoptosis [30]. These apoptotic and anti-apoptotic
interactions contribute to the cell’s fate, and it is well
known that the apoptotic pathway can be regulated by the
formation of homo- and heterodimers of both apoptotic
and anti-apoptotic factors [31]. Moreover "in vitro" experi-
ments demonstrate that small differences in the amount of
Bcl-2 and Bcl-xL lead to large differences in cell survival.
This was particularly evident for Bcl-xL that is about ten
time more efficient than Bcl-2 in preventing doxorubicin
induced apoptosis in MCF-7 breast cancer cell lines [32].
The quantitative and qualitative differences in Bcl-2 and
Bcl-xL protein activity in inhibiting apoptosis seems to de-
pend by changes in their subcellular localisation.
The mitochondrial membrane represent the principal
site of Bcl-2 family proteins for apoptosis regulation. How-
ever, recently Bcl-2 family members are present on the ER,
were they seem to have more extensive functions. Only in
the ER indeed, Bcl-2 or Bcl-xL inhibits autophagy [33].
Interactions between Beclin 1 and apoptotic mediators in
liver diseases
Beclin-1 was originally discovered as a protein interacting
with Bcl-2; it contains a BH3 domain crucial to its bindingto anti-apoptotic factors [34]. Beclin 1/Bcl-2 and Beclin 1/
Bcl-xL heterodimers may inhibit autophagy, but only in the
ER. The debate on the topic is however still open, since
Priault et al. [35], using an in vitro model based on HCT116
cell lines, demonstrated that the subcellular localization of
Bcl-xL was modified by starvation and, in particular, that
Bcl-xL acts on the whole independently of Beclin 1, helping
the formation of autophagosomes.
We did not investigate the levels of these heterodimers in
our tissues, but it is clear that liver tissues with chronic liver
damage (caused by either HBV or HCV infection) expressed
higher levels of Beclin 1, Bcl-xL and Bad transcripts than
peritumoral or tumor tissues. With respect to the type of
virus involved, we observed that tissues HBV-related CH
revealed higher levels of Bad and Bcl-xL mRNA transcripts
than HCV-related CH, while no difference was seen in
Beclin 1 expression.
The X protein of HBV (HBx) has been shown to contain a
BH3 domain [36] that may interact with and inhibit Bcl-xL.
Hong Tang et al. conducted in vitro studies using hepatoma
cell lines and demonstrated that HBx upregulates endogen-
ous Beclin 1 mRNA and protein expression levels [37]. In
our HBV-related tissues, activation of the apoptotic pathway
seems to be facilitated at the expense of autophagy, as con-
firmed by the predominant expression of apoptotic factors in
these tissues. We need to bear in mind, however, that in
HBV infection, HBx is produced in the infected cells at
much lower levels than in transfection experiments.
The low levels of Beclin 1, Bcl-xL and Bad mRNA
observed in HCC support their relationship in promoting
tumorigenesis and favoring tumor cell progression. This re-
lationship is confirmed by the significant positive correla-
tions found between Beclin 1 and Bcl-xL in these tissues. A
strong positive correlation between tumoral/non tumoral
ratio of Beclin 1 mRNA and Bcl-xL mRNA in HCC was also
reported by Daniel F et al. [24].
It is worth emphasizing our observation that it was only in
PHCC liver tissues that no correlations emerged between
Beclin 1 and Bcl-xL, and only in these tissues that positive
correlations were seen between Beclin 1 and Bad (P=0.03)
and between Bax and Bcl-2 (P=0.01). Bax and Bak are essen-
tial for cell death, they directly induce mitochondrial dysfunc-
tion, and are often mutually supplemental, i.e. the expression
of one compensates for the lack of the other [38]. On the
other hand, the overexpression of Bcl-2 has been demon-
strated to prevent the efflux of cytochrome c from the mito-
chondria and subsequent initiation of apoptosis [39] and the
increase Bcl-2 expression could be important in the counter-
act the effect of Bax. The cross-talk between mitochondria
and endoplasmic reticulum (ER) is controlled by Bcl-2 and
the relative levels and interactions of Bax, Bad and Bcl-2, and
their homodimerization or heterodimerization, may act like
chekpoints in determining the life or death of the cell

































Figure 5 Schematic representation of the interplay between pro- and anti-apoptotic Bcl-2 family members and Beclin 1, in the
endoplasmic reticulum and mitochondria.
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our experience it looks like that the Bcl-2 overexpression
characterizes only the late phases of the disease i.e. when
HCC develops, while Bcl-xL expression begins in earlier
phases of the disease itself. As seen in a previous study on the
apoptotic process, it is reasonable to assume that the im-
munological anti-tumoral activity and cell death [40] process
is concentrated mainly in the cirrhotic tissues surrounding a
tumor, where the presence of large numbers of lymphocytes,
monocytes/macrophages and Kupffer cells releasing large
quantities of ROS and cytokines [41] may prompt the upre-
gulation of apoptotic factors such as Bax, Bad and Bcl-2. A
decrease in Beclin 1 mRNA levels would point instead to an
imbalance between apoptosis and autophagy mediators prob-
ably favoring the apoptotic process. Both these processes
seem to be downregulated in HCC, confirming that the sur-
vival of tumor cells in the liver relies on their evading both
apoptotic and autophagocytic cell death.Conclusions
In conclusion, autophagy and apoptosis in the liver are
interconnected processes that are overexpressed in the early
and intermediate stage of viral hepatitis. The high levels of
Beclin 1 observed in CH and CIRR tissues suggest a centralrole for autophagy as a stress-responsive pathway that may
limit liver damage and interact with progression to cancer.
HBV infection seems to play a key role through the in-
duction of expression of Bcl-xL transcripts, that are import-
ant for the neutralization of autophagic Beclin 1 protein.
The highest Bcl-2 mRNA levels and the positive correl-
ation between Bcl-2 and Bad observed in PHCC indicate
that these tissues represent a complex hepatic microenvir-
onment were most of the inflammatory, proliferative and
anti-tumoral activity takes place.
The low expression of Beclin 1, Bcl-xL and Bad we
demonstrated in HCC patients points to a reduced autop-
hagy that may favor the onset and progression of tumor.
A better understanding of the interplay between mechan-
isms of cell survival and cell death involved in liver disease
progressing from chronic infection to cirrhosis and HCC
certainly carries great potential for the development of spe-
cific treatments.
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